FDA Clears Denali Drug for Hunter Syndrome Amid Tightened Rare-Disease Scrutiny
The FDA approved Denali Therapeutics' Avlayah for Hunter syndrome, marking a rare-disease drug approval at a time regulators are signaling tougher evidentiary standards after recent rejections like Regenxbio's Hunter syndrome gene therapy.